Literature DB >> 26265830

Snake venom ophthalmia.

Vijay Kumar Sharma1, V K Baranwal2.   

Abstract

Entities:  

Keywords:  Cardiotoxin; Envenomation; Snake venom ophthalmia

Year:  2014        PMID： 26265830      PMCID： PMC4529546          DOI： 10.1016/j.mjafi.2014.01.003

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN： 0377-1237


× No keyword cloud information.
  5 in total

Review 1.  Venom ophthalmia caused by venoms of spitting elapid and other snakes: Report of ten cases with review of epidemiology, clinical features, pathophysiology and management.

Authors:  Edward R Chu; Scott A Weinstein; Julian White; David A Warrell
Journal:  Toxicon       Date:  2010-03-21       Impact factor: 3.033

2.  Effects of topical heparin, antivenom, tetracycline and dexamethasone treatment in corneal injury resulting from the venom of the black spitting cobra (Naja sumatrana), in a rabbit model.

Authors:  Gregory Cham; James Chuan-Hsin Pan; Francis Lim; Arul Earnest; P Gopalakrishnakone
Journal:  Clin Toxicol (Phila)       Date:  2006       Impact factor: 4.467

3.  Functional bases of the spatial dispersal of venom during cobra "spitting".

Authors:  Bruce A Young; Melissa Boetig; Guido Westhoff
Journal:  Physiol Biochem Zool       Date:  2009 Jan-Feb       Impact factor: 2.247

4.  Membrane-bound conformation of Naja nigricollis toxin gamma affects its membrane-damaging activity.

Authors:  Pei-Hsiu Kao; Ming-Jung Wu; Long-Sen Chang
Journal:  Toxicon       Date:  2008-12-11       Impact factor: 3.033

5.  Local antivenom treatment for ophthalmic injuries caused by a Naja atra.

Authors:  Hin Tat Fung; Ka Keung Lam; Oi Fung Wong; Tommy Shing Kit Lam
Journal:  J Med Toxicol       Date:  2010-06
  5 in total
  1 in total

1.  A Neurotoxic Snake Venom without Phospholipase A2: Proteomics and Cross-Neutralization of the Venom from Senegalese Cobra, Naja senegalensis (Subgenus: Uraeus).

Authors:  Kin Ying Wong; Kae Yi Tan; Nget Hong Tan; Choo Hock Tan
Journal:  Toxins (Basel)       Date:  2021-01-14       Impact factor: 4.546
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.